This slide show reports on a pooled analysis that found up to a fivefold risk of second cancers among smokers, compared with cancer survivors who never smoked.
FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma
The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.
Charting the Evolution of TKIs and Finding the Next Breakthrough in CML
Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
Anticipated data from the ESMO Congress 2025 may have implications for standards of care across prostate and bladder cancer groups.
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
The novel PET imaging agent detected significantly more PSMA-positive prostate cancer lesions vs SOC in patients with low PSA levels.
FDA Grants Fast Track Designation to NG-350A For pMMR Rectal Cancer
Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.